Philadelphia College of Osteopathic Medicine

DigitalCommons@PCOM
PCOM Psychology Dissertations

Student Dissertations, Theses and Papers

2019

The Effect of Social Problem-solving, Health
Anxiety, and Psychological Distress on Breast
Cancer Genetic Testing Decisions in a Sample of
Healthy Women
Alexandria Muench
Philadelphia College of Osteopathic Medicine

Follow this and additional works at: https://digitalcommons.pcom.edu/psychology_dissertations
Part of the Clinical Psychology Commons
Recommended Citation
Muench, Alexandria, "The Effect of Social Problem-solving, Health Anxiety, and Psychological Distress on Breast Cancer Genetic
Testing Decisions in a Sample of Healthy Women" (2019). PCOM Psychology Dissertations. 514.
https://digitalcommons.pcom.edu/psychology_dissertations/514

This Dissertation is brought to you for free and open access by the Student Dissertations, Theses and Papers at DigitalCommons@PCOM. It has been
accepted for inclusion in PCOM Psychology Dissertations by an authorized administrator of DigitalCommons@PCOM. For more information, please
contact library@pcom.edu.

i

Philadelphia College of Osteopathic Medicine
Department of Psychology

THE EFFECT OF SOCIAL PROBLEM-SOLVING, HEALTH ANXIETY,
AND PSYCHOLOGICAL DISTRESS ON BREAST CANCER GENETIC TESTING
DECISIONS IN A SAMPLE OF HEALTHY WOMEN

By Alexandria Muench
Submitted in Partial Fulfillment of the Requirements for the Degree of
Doctor of Psychology
May 2018

PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE
DEPARTIVIENT OF PSYCHOLOGY
Dissertation Approval

This is to certify that the thesiS presented to us by
on the

4

dayof

MtA.j

A-It: )(et. V\ d V\

1
.()\

Mve.n Gh

Ji, in partial fulfillment of the

, 20

requirements for the degree of Doctor of Psychology, has been examined and is
acceptable in both scholarship and literary quality.

Conmtlttee lVIembers' Si!!natures:
Chairperson

·Chair, Department of Psychology

ii
Acknowledgements
The successful completion of this dissertation would not have been possible
without the ongoing support, mentorship, and encouragement of my dissertation
committee, supervisors, mentors, family, and friends. I would like to first thank Dr.
Stephanie Felgoise, whose unyielding support has made the dissertation process and
graduate school an experience of tremendous professional and personal growth. Dr.
Felgoise is a constant source of inspiration and has never failed to make me laugh, even
as the program became more arduous. Second, I would like to thank Dr. Christina
Shook, who began as a practicum supervisor but has become a lifelong mentor and
colleague. Dr. Shook brings compassion, perseverance and kindness to all that she does
and believed in me far before I recognized the importance of believing in myself. I
would also like to thank Dr. Stephen Poteau, for his assistance throughout the entire
dissertation process.
Next, I would like to thank my best friend and sister, Nicole, for being an endless
source of love, laughs, encouragement, and support throughout this program. I am
grateful to have had such a wonderful person to share this experience with. I would like
to thank Megan, who has been there with words of encouragement every step of the way
and always provided her couch to sleep on when the drive home was too long. I am
beyond thankful for my University of Pennsylvania family who have provided me
endless opportunities and have been cheering me on as I progressed through the program.
I would like to thank my parents, Winnie and Gregg, my sister, Staci, my aunt and
uncle, Candy and Rich, for their unconditional and unrelenting patience, love, and
support throughout all of my educational endeavors. Finally, although they have passed

iii
on, none of this would have been possible without my grandparents, Sigrun and William,
who instilled a love of learning in me that has continued to prevail. I love you both very
much.

iv
Abstract
Breast cancer is a leading cause of death in women in the United States, with hereditary
breast cancers accounting for approximately 10% of the diagnoses. Nevertheless, women
can decrease their risk by obtaining genetic testing and are often referred for the test if
one or more of their relatives has been diagnosed with breast cancer and has the
BRCA/BRCA2 cancer mutation. The purpose of the current study was to examine
predictors of healthy women’s (ages 18 to 35) hypothetical decisions about genetic
testing and prophylactic treatments for the BRCA1/BRCA2 genetic mutations by
measuring social problem solving (SPS) variables, health anxiety, and psychological
distress. A survey format to was used to determine whether there was a relationship
between these variables, genetic testing, and/or prophylactic treatment decisions.
Measures included the Social Problem-Solving Inventory-Revised, Short Form (SPSIR:S), Health Anxiety Inventory (HAI), Brief Symptom Inventory (BSI), a demographic
questionnaire, and two hypothetical vignettes. Results revealed that positive problemsolving orientation (PPO) is predictive of prophylactic treatment decisions. The results
support the literature in that genetic testing decisions are difficult to predict, and other
factors that have yet to be determined may be contributing to the decision. Future
research should look at these relationships in larger non-hypothetical samples and in
different disease groups to determine whether the results differ.

v
Table of Contents
List of Tables ..................................................................................................................... ix
Chapter 1: Introduction ....................................................................................................... 1
Statement of the Problem ........................................................................................ 1
Purpose of the Study ............................................................................................... 4
Chapter 2: Literature Review .............................................................................................. 5
Genetic Basis of Breast Cancer............................................................................... 5
BRCA1/BRCA2 Risk Factors................................................................................. 6
Race and Ethnicity .................................................................................................. 9
Genetic Testing ..................................................................................................... 10
Genetic Testing and Psychological Variables. ...................................................... 12
Psychological distress ............................................................................... 12
Health anxiety ........................................................................................... 15
Social problem-solving ............................................................................. 17
Problem orientation .................................................................................. 18
Problem-solving style................................................................................ 20
Problem-solving training .......................................................................... 21
Prophylactic Treatment ......................................................................................... 22
Summary ............................................................................................................... 23
Chapter 3: Hypothesis ....................................................................................................... 25
Hypothesis............................................................................................................. 25
Rationale ............................................................................................................... 25
Chapter 4: Method ............................................................................................................ 27

vi
Research Design and Design Justification ............................................................ 27
Participants and Recruitment ................................................................................ 27
Inclusion criteria ....................................................................................... 27
Exclusion criteria. ..................................................................................... 28
Recruitment ............................................................................................... 28
Procedure .............................................................................................................. 28
Security ..................................................................................................... 29
Measures ............................................................................................................... 29
Clinical vignettes ...................................................................................... 29
Social Problem-Solving Inventory-R:S (SPSI-R:S) ................................. 29
Short Health Anxiety Inventory (SHAI) ................................................... 30
Brief Symptom Inventory-18 (BSI-18) ..................................................... 31
Chapter 5: Results ............................................................................................................. 32
Statistical Analysis. ............................................................................................... 32
Demographic Information ..................................................................................... 32
Health Behaviors ................................................................................................... 34
Hypothetical Vignettes.......................................................................................... 35
Social Problem-Solving ........................................................................................ 36
Health Anxiety ...................................................................................................... 37
Psychological Distress .......................................................................................... 38
Stepwise Regression Analysis: Vignette 2 ........................................................... 39
Chapter 6: Discussion ....................................................................................................... 41
Demographic Variables ........................................................................................ 41

vii
Psychological Distress, Health Anxiety, and Social Problem-Solving................. 45
Implication of the Research Findings ................................................................... 48
Limitations of Current Study ................................................................................ 51
Future Directions .................................................................................................. 52
References ......................................................................................................................... 54
Appendix: Clinical Vignettes ............................................................................................ 73
Endnotes............................................................................................................................ 74

viii
List of Tables
Table 1. Risk Modifiers in BRCA1/BRCA2 Mutation Carriers ........................................ 8
Table 2. Age-Adjusted Rates of Diagnosis and Survival by Race in Breast Cancer ....... 10
Table 3. Participant Demographics .................................................................................. 33
Table 4. Vignette 1: Descriptive Statistics Table............................................................. 36
Table 5. Vignette 2: Descriptive Statistics Table............................................................. 36
Table 6. Social Problem-Solving Inventory-Revised, Short Form Descriptive
Statistics ........................................................................................................................... 37
Table 7. Short Health Anxiety Inventory Descriptive Statistics ...................................... 38
Table 8. Brief Symptom Inventory-18 (Scaled Scores) Descriptive Statistics ................ 38
Table 9. Stepwise Regression Model Summary .............................................................. 39
Table 10. Stepwise Regression Model Summary, Change Statistics............................... 39
Table 11. Stepwise Regression Model Summary, Excluded Variables ........................... 40
Table 12. ANOVA ........................................................................................................... 40
Table 13. Collinearity Coefficients .................................................................................. 40

Chapter 1: Introduction
Statement of the Problem
Second to skin cancer, breast cancer is the most commonly diagnosed cancer in
the United States (accounting for one in three cancers) and, after lung cancer, it is a
leading cause of cancer-related cause of death in women (DeSantis, Ma, Bryan & Jemal,
2014). In families with no history of breast cancer, the risk of developing breast cancer
by age 30 is 4.07% and by age 50, the risk more than doubles to 8.76% (Bleyer & Welch,
2012). Moreover, as of 2016, it was estimated that there were more than 3.5 million
women with a history of invasive breast cancer living in the United States (Miller et al.,
2016). Compared to other cancers, breast cancer is typically diagnosed at younger ages
(breast cancer median age = 61; lung cancer median age = 70; colorectal cancer median
age = 68).
Although the incidence of breast cancer remains fairly low in the general
population, hereditary breast and ovarian cancers (HBOC)—breast and ovarian cancers
with a hereditary basis—occur in approximately 10% of the population (Daly et al. 2010;
Howlader et al., 2012). HBOC are most commonly caused by mutations, also known as
deleterious variances, in the BRCA1 and BRCA2 genes (D. M Eccles et al., 2015).
Although the BRCA1/BRCA2 genes are implicated in the development of breast cancer,
they only account for 20% of hereditary breast cancers, as a number of other hereditary
cancer susceptibility genes have been identified (Antoniou et al., 2003; Crawford et al.,
2017; D. M. Eccles et al., 2015).
Due to the high heritability of the BRCA1/BRCA2 mutations, first degree
relatives (FDRs; those who have had a parent and/or sibling diagnosed with breast
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cancer) are often referred for genetic testing services (Crawford et al., 2017). For
instance, genetic testing is encouraged if the FDR meets certain criteria, including but not
limited to a history of breast cancer prior to the age of 50 in one or more first-degree
relative(s), a family member with a known BRCA1/BRCA2 mutation, a family history of
breast cancer in one or more first-degree relatives (particularly if they are diagnosed at
younger ages), and a family member with the BRCA1/BRCA2 genetic mutation (Daly et
al., 2010; Wevers et al., 2011). Genetic testing can reduce risk, but it can also be
uncertain and anxiety provoking. Given that genetic testing is inherently ambiguous, for
some people it can have negative psychological consequences (i.e., psychological distress
or health anxiety; Butow, Lobb, Meiser, Barratt, & Tucker, 2003). For example, the
amount of uncertainty that one has about genetic testing has been found to be related to
psychological distress (Frost, Venne, Cunningham & Gerritsen-McKane, 2004).
Although uncertainty is a natural consequence of genetic testing, high degrees of
uncertainty are considered to be related to knowledge of individual risk versus perceived
risk, communication with genetic counselors (i.e., feeling fully informed), and uncertain
genetic testing results (Croyle, Smith, Botkin, Baty, & Nash, 1997; Frost et al., 2004).
Nevertheless, even with high levels of uncertainty, premorbid levels of psychological
distress have been found to be strong predictors of the degree of distress experienced
post-testing (Reichelt, Heimdal, Møller, & Dahl, 2004).
Health anxiety is the anxiety that is brought on, maintained, and exacerbated by
health-related stimuli and can be an understandable effect as people move through the
genetic testing and prophylactic treatment process (Starcevic, 2013). Health anxiety can
arise or become exacerbated at any time, such as before testing or treatment or while
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waiting for the results or surgery, and even if the results are negative, health anxiety can
remain after the results have been received or after the surgery has happened. To
illustrate, Rimes and Salkovskis (2002) identified four factors that are thought to be
fundamental to the perception of threat and the subsequent experience of genetic testing
related health anxiety: (a) perceived likelihood that the illness will develop, (b) perceived
severity of illness course, (c) perceived ability cope with the illness, and (d) level of
support that will be available if the illness were to develop. In addition, self-esteem and
self-efficacy are considered to moderate the amount of health anxiety that is experienced
(Audrain et al., 1997).
The process of making genetic testing and prophylactic treatment decisions is
complicated, as it requires people to make fairly quick life-altering decisions. Social
problem-solving (SPS) can assist in this endeavor and is defined as the problem-solving
skills that people use in their natural environments (D’Zurilla & A. M. Nezu, 1982). SPS
is helpful in stressful situations and has been found to be predictive of overall adjustment
and emotional well-being (Chang, D’Zurilla, & Sanna, 2004; D’Zurilla & A. M. Nezu,
1982; Dreer et al., 2009). For example, Dreer et al. (2009) conducted correlational
research demonstrating that positive problem-solving abilities (i.e., identifying the
problem, weighing pros and cons of solutions) relate to a decrease in depression in those
with chronic diseases and their caregivers.
Not surprisingly, positive problem-solving yields positive health outcomes,
including a more positive perception of overall health, engagement in healthy lifestyle
behaviors (i.e., exercise), and adherence to medical recommendations (Dreer, Elliott &
Tucker, 2004; Elliott & Shewchuk, 2003). In fact, when SPS skills are taught to breast
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(McClure, A. M. Nezu, C. M. Nezu, O’Hea, & McMahon, 2012). In sum, strong
problem-solving skills appear to be associated with multiple positive health-related
outcomes and, when applied effectively, may protect against psychological distress and
health anxiety.
Purpose of the Study
The purpose of this study was to examine the factors that may predict FDR’s
BRCA1/BRCA2 genetic testing and prophylactic decisions by providing hypothetical
vignettes to a sample healthy of women between the ages of 18 and 35. The current
study evaluated whether SPS variables (i.e., problem-solving orientation, rational
problem solving, avoidance style, and impulsivity/carelessness style), psychological
distress, and health anxiety predict a healthy FDR’s hypothetical choice to have genetic
testing. Information gained from this study may provide further insight into the genetic
testing and prophylactic treatment decision making process.
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Chapter 2: Literature Review
Breast cancer is the most commonly diagnosed invasive cancer in women in
North America and the second leading cause of cancer death in the United States (Ban &
Godellas, 2014). In 2017, there was an estimated 252,710 new breast cancer diagnoses
(15% of all cancer diagnoses) and approximately 40,610 breast cancer related deaths
(6.8% of all cancer deaths; Surveillance, Epidemiology, and End Results Program
[SEER], 2017). Nevertheless, advances in medicine (i.e., adjuvant therapy) and medical
technology (i.e., screening advances) have led to earlier breast cancer detection and
decreased mortality rates (1975i: 105.1 new cases, 31.4 new deaths; 2014iii: 125.3 new
cases, 20.5 new deathsiv; Plevritis et al., 2018; SEER, 2017).
Genetic Basis of Breast Cancer
When working correctly, BRCA1/BRCA2 tumor suppressor proteins play an
important role in repairing damaged deoxyribonucleic acid (DNA; Majdak-Paredes &
Fatah, 2009). These proteins are integral in securing each cell’s genetic material and,
therefore, stopping abnormal cell growth (Majdak-Paredes & Fatah, 2009). As a result of
their function, mutations in either protein can lead to tumor growth. The
BRCA1/BRCA2 mutations are inherited from either parent (autosomal dominant) and
occur equally in men and women; however, women are disproportionately affected
(Hamilton, Lobel, & Moyer, 2009; Struewing et al., 1997). These mutations exhibit
incomplete penetrance (i.e., not everyone who inherits the gene will develop cancer;
Parmigiani, Berry, & Aguilar, 1998). The relationship between the mutation and cancer
risk is determined not only by genetic factors but by environmental factors as well
(Hamilton et al., 2009).
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When a BRCA1/BRCA2 mutation is inherited, it is classified as BRCA1/BRCA2associated HBOC (Petrucelli, Daly, & Pal, 2016). In women, BRCA1/BRCA2associated HBOC increases risk for breast and ovarian cancers, pancreatic cancer, and
melanoma (cutaneous and ocular; Petrucelli et al., 2016). Although not entirely within
the scope of this paper, there are additional hereditary breast cancer syndromes that are
caused by mutations in other proteins (Thull & Vogel, 2004). Additional hereditary
breast cancer syndromes include site-specific breast cancer (which may be associated
with mutations in the BRCA1/BRCA2 genes), Cowden syndrome (CS) or multiple
hamartoma syndrome, LieFraumeni syndrome (LFS), Peutz-Jegher syndrome (PJS),
ataxia-telangiectasia (AT) syndrome, and low-penetrance breast cancer allele
CHEK2*1100delC (Thull & Vogel, 2004). The risk for HBOC cancers are dependent on
which mutation occurs (BRCA1 or BRCA2; Petrucelli et al., 2016).
BRCA1/BRCA2 Risk Factors
Having a comprehensive knowledge of the risk factors for the BRCA1/BRCA2
mutation is the first step in making informed prophylactic treatment decisions (i.e.,
mastectomy and oophorectomy). Recent literature suggests that awareness of risk prior
to genetic testing can predict levels of psychological distress post-testing (higher risk
increases psychological distress; Cicero et al., 2017; Himes et al., 2016). Yet, even with
this knowledge, the risk factors are complex and uncertainty persists pre- and posttesting. Genetic testing is typically recommended in patients who have personal and/or
family histories (first, second, or third degree relative) and any of the following
characteristics: (a) two or more family members diagnosed with breast cancer, with at
least one diagnosed at less than 50 years of age; (b) three or more family members
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diagnosed with breast cancer at any age; (c) family history of male breast cancer; (d) a
breast cancer diagnosis prior to age 51; I past or current diagnosis of ovarian cancer; (f)
history of multiple primary breast cancers in one or both breasts; (f) personal or family
history of triple-negative (estrogen receptor-negative, progesterone receptor-negative,
and human epidermal growth factor receptor [HER2/neu] 2-negative) breast cancer,
particularly when diagnosed before age 60 years; (g) a relative with the BRCA1/BRCA2
mutation (Kim, Puymon, Qin, Guru, & Mohler, 2013).
In HBOC families at high risk for the BRCA1/BRCA2 mutation, age is an
important factor. The U.S. Preventive Services Task Force (USPSTF) reviewed the
literature and provided recommendations for risk assessment, genetic counseling, and
genetic testing for the BRCA1/BRCA1 mutations for asymptomatic women with a family
history of breast or ovarian cancer (Moyer, 2014). The USPSTF recommends women
from high risk families undergo genetic testing at age 18, even though the risk of
developing breast cancer in the 18 to 24 age range is only approximately 1% (Moyer,
2014; Patenaude et al., 2013).
Despite low risk in some women who test positive, decreasing the risk of breast
cancer begins early and continues throughout the lifespan. The National Comprehensive
Cancer Network (NCCN; 2018) outlined the following guidelines for BRCA mutationpositive women: (a) women between the ages of 18 and 24 should begin monthly breast
self-exams (BSE) at the end of menses, (b) at age 25, BRCA1/BRCA2 positive mutation
carriers are highly advised to begin receiving clinical breast exams from their
obstetrician-gynecologist (OB-GYN) every 6 to 12 months and getting annual breast

PROBLEM-SOLVING AND CANCER DECISIONS

8

MRIs with contrast, and (c) from age 30 to 75, women are strongly encouraged to
continue to receive their annual breast MRIs along with annual mammographies.
In addition to age, environmental factors can increase the risk of developing
breast cancer in mutation carriers (Friebel, Domchek, & Rebbeck, 2014). In a metaanalysis completed by Friebel et al. (2014), 44 studies were reviewed to assess for
potential BRCA1/BRCA2 protein risk modifiers. Certain reproductive factors and
environmental exposures were found to influence breast cancer risk separately in each
gene, specifically oral contraceptive use, smoking (greater than 4 years), nulliparity, and
earlier age at menarche (Table 1; Friebel et al., 2014).

Table 1
Risk Modifiers in BRCA1/BRCA2 Mutation Carriers
Reproductive





Exposures

BRCA1
Nulliparity versus Parity:
Each live birth decreases
risk




Breastfeeding: Reduced
risk if breastfeeding
occurred for longer than
one year

BRCA2
Nulliparity versus Parity:
More than three live
births decreases risk
Breastfeeding: Null
results reported



Age at Menarche: Null
results reported



Age at Menarche:
Reduced risk with later
age



Oral contraceptive use:
Increased risk



Oral contraceptive use:
Increased risk



Smoking: Possible risk.
Results inconsistent.



Smoking: Increased risk

Note. Data for risk modifiers in BRCA1/BRCA2 mutation carriers from Friebel et al. (2014)
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Race and Ethnicity
Even with advancements in medical treatment and technology, there continues to
be racial and ethnic differences in diagnosis, survival, and treatment access (Iqbal,
Ginsburg, Rochon, Sun, & Narod, 2015). This has been found to be especially true in
African American women, about whom there has been research to support differences
between the biology of their tumors and those of other races/ethnicities (Iqbal et al.,
2015). For example, Newman et al. (2006) identified 20 studies in which survival rates
were reported and found that, even after adjusting for socioeconomic status (SES),
African American ethnicity was an independent and significant predictor of poorer
survival from breast cancer. In regard to treatment access, McCarthy et al. (2016)
reported differences in recommendations for BRCA1/BRCA2 testing between white and
black women, where black women are less likely to receive a recommendation for
genetic testing from an oncologist or surgeon. While the reasons were unclear the authors
suggested the physician’s concerns about costs and lack of insurance coverage and the
possibility of an incomplete family history (McCarthy et al., 2016; Murff, Byrne, Haas,
Puopolo, & Brennan, 2005). Samson et al. (2016) also showed that despite being
screened for breast cancer, Black women are at a higher risk of being diagnosed in later
stages and having a poorer chance for survival. Low adherence, which can be accounted
for by socioeconomic factors, may contribute to these findings (e.g.,, lack of insurance
leading to nonadherence to treatment recommendations; Adams et al., 2009).
Women minorities are also often suspicious of their medical providers,
subsequently increasing the chance for low adherence and poor treatment outcomes
(Table 2; Matthews, Sellergren, Manfredi, & Williams, 2002). To combat the patient’s
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uneasiness, evidence suggests that medical providers should pay close attention to their
own biases, as they can impact patients’ communication styles and self-concepts (Ashton
et al., 2003). Additional recommendations include providing adequate time and
appropriate prompts to allow the patient ask questions and express concerns (Ashton et
al., 2003).

Table 2
Age-Adjusted Rates of Diagnosis and Survival by Race in Breast Cancer

Non-hispanic white
Black
Hispanic American
Asian

Age-adjusted
diagnosis rates
(per 100,000)

Survival rates
(crude 10-year)

129
123
94
93

80%
66%
82%
78%

Note. Data for rates of diagnosis and percentage of survival from Howlader et al. (2012)

Genetic Testing
Genetic testing is a type of medical test that identifies mutations in DNA proteins
(Calzone & Biesecker, 2002). Genetic tests are routinely performed prenatally to assess
for chromosome abnormalities in the fetus (Calzone & Biesecker, 2002). Outside of
prenatal care, genetic testing is now being used to assess for risk for various diseases
(Calzone & Biesecker, 2002). The three types of genetic testing that are available are
carrier, pre-symptomatic, and predisposition. Carrier testing is typically done to look at
reduced enzyme activity in recessive gene mutations, as reduced enzyme activity can be
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indicative of specific types of gene mutations (e.g., cystic fibrosis; Mansoura & Collins,
1998). In conditions such as Alzheimer’s disease, pre-symptomatic testing determines
with certainty if the disease will develop. Finally, predisposition testing is used in
healthy people to determine their risk of developing a disease (e.g., BRCA1/BRCA2
mutation; Mansoura & Collins, 1998).
Predisposition testing is linked to an increase in distress and anxiety because of
the chance for uncertain outcomes, as testing results can be positive or negative, and
include variants of uncertain significance (VUS) falling between 0.05 and 0.949
probability of pathogenesis (B. K. Eccles, Copson, Maishman, Abraham, & D. M. Eccles,
2015; Lumish et al., 2017). Moreover, the incidence of VUS differs based on race and
ethnicity (African Americans = 21%; European Americans = 5% to 6%; Lindor, Goldgar,
Tavtigian, Plon, & Couch, 2013). Lumish and colleagues (2017) surveyed 232 patients
with HBOC who had previously undergone pre-symptomatic genetic testing and found
that those who reported increased distress had no prior history of cancer and had received
a VUS. Conversely, patients who have received pre-symptomatic genetic testing for
Huntington’s disease (HD) trend toward less distress post-testing, but this result is
contingent on whether one is a mutation carrier and the disease in question, as being a
mutation carrier in HD means that there is a 100% chance that the disease will develop
(Crozier, Robertson, & Dale, 2015).
Genetic testing uptake rates vary and are determined by a myriad of factors,
including personal and/or family history of breast cancer. For instance, among FDRs, the
possibility that a positive test could mean the need for prophylactic treatment can
complicate matters further and increase the risk for the onset of psychological distress
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(Metcalfe et al., 2010; Schwartz et al., 2002). Another factor contributing to the
complexity of genetic testing and prophylactic decisions is that genetic testing uptake
rates vary; research has yet to determine exactly what causes this variability. It is clear
that personal and/or family history of breast cancer impacts decisions, but the type of
research design (e.g., hypothetical vs real) appears to have an impact on the amount of
genetic testing uptake that is reported (Ropka, Wenzel, Phillips, Siadaty & Philbrick,
2006). For example, Ropka et al. (2006) systematically reviewed 40 studies and
determined that the mean genetic testing uptake in BRCA1/BRCA2 FDRs was 66%
(range = 20% to 96%) in hypothetical studies and 59% (range = 25% to 96%) in real
scenarios. To summarize, the large amount of variance in genetic testing and
prophylactic treatment uptake rates are most likely due to study methodology as well as
the variety of personal and environmental factors that contribute to the decision.
Genetic Testing and Psychological Variables
Psychological distress. As genetic testing has been on the rise, so has the
discussion about the role that psychological variables play in the process. Psychological
distress is defined as a persistent worry, anxiety, and decreased mental health in response
to a stressful life event (Audrain et al., 1997). Baum, Friedman, and Zakowski (1997)
proposed a model, based on Lazarus and Folkman’s (1984) theory of stress and coping to
explain the relationship between stress and genetic testing. The authors proposed that
individuals at risk for genetically inherited diseases that received positive results and
were also low in coping skills, support, and/or psychosocial resources would have higher
stress levels (Baum, Friedman, & Zakowski, 1997).
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Similarly, Hamilton and Bowers (2007) developed a theory of genetic
vulnerability where they outlined six concepts that contribute to one’s distress pre and
post-testing: (a) experiencing cancer within the family, (b) testing for a mutation, (c)
understanding disease risk, (d) foregrounding the disease, (e) responding to knowledge of
genetic vulnerability, and (f) altering or avoiding the family history of disease.
In addition, a prior occurrence of cancer in the family can influence how one copes
throughout the genetic testing and prophylactic process (Hamilton & Bowers, 2007).
In other words, the authors found that a past history of cancer in the family can
impact perceived risk, the amount of distress that is felt in respect to telling one’s family
about the test result (i.e., foregrounding: bringing the disease to the forefront), the ability
to cope with the results of the genetic test, and how one incorporates the information into
one’s prior experiences with the disease (Hamilton & Bowers, 2007). Ultimately, the
decision-making process is highly influenced by past experiences, especially if the cancer
occurred within the immediate family system (Hamilton & Bowers, 2007).
Although not applied formally, the themes of Baum et al. (1997) and Hamilton
and Bowers (2007) are seen throughout the BRCA1/BRCA2 genetic testing literature.
For example, Fletcher et al. (2006) determined factors associated with psychological
distress in first-degree female relatives (N = 624) of newly diagnosed cancer patients.
Fletcher and colleagues found that greater optimism was associated with low cancerrelated and general distress; however, avoidance of disease-related stimuli and a close
relationship with the cancer patient resulted in higher levels of cancer-specific distress
and low levels of general distress (Fletcher et al., 2006).
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Ringwald et al. (2016) reviewed 1,243 studies that included measures of
psychological distress, anxiety, and depression among cancer-affected BRCA1/BRCA2
mutation carriers post-genetic testing. The results of this review were contradictory. In
general, a positive test result increased depression, distress, and anxiety for 12 months
post-testing (Ringwald et al., 2016); however, the authors also identified multiple studies
which found the opposite, in which both cancer-affected and non-affected mutation
carriers did not display increased levels of depression or anxiety (e.g., Claes et al. 2004;
Schwartz et al. 2002).
Smith et al. (2008) also assessed psychological distress and quality of life in those
with a family and personal history of breast cancer. Interestingly, findings indicated that
women who declined to be tested reported a higher incidence of distress compared to
women who received negative or uncertain results. Consistent with previous literature,
women who received a positive result experienced heightened distress for a short period
of time (approximately three months), with distress levels returning to baseline a few
months after the results were received (Smith et al., 2008).
In general, it is clear that there is significant variability with regard to the way
people respond to and are affected by genetic testing decisions. The inconsistency in the
psychological distress literature could be attributed to individual variation in decision
making and problem-solving processes, availability of pre-testing genetic counseling
services, levels of general psychological distress pre-testing, demographic variables, past
history of cancer, and past psychiatric history (e.g., premorbid depression and anxiety;
Catania et al., 2016; Reichelt, Møller, Heimdal, & Dahl, 2008; Ringwald et al., 2016).
Overall, the research demonstrates several themes: (a) genetic testing can prove
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psychologically beneficial for many individuals, (b) not knowing results of genetic
testing tends to have a negative impact on distress levels, and (c) perceived risk (i.e., the
amount of risk a person thinks he or she has of developing the disease) seems to be
heightened in women who decline genetic testing. Given the inconsistent findings, more
research is needed understand fully how genetic testing decisions are made and the
psychological impact that occurs both pre- and post-testing and in regard to prophylactic
treatment.
Health anxiety. Health anxiety—which has a lifetime prevalence of
approximately 5% and is now classified as illness anxiety disorder in the fifth edition of
the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)—is persistent
anxiety about health that includes little to no somatic complaint (American Psychiatric
Association, 2013; Starcevic, 2013; Tyrer et al., 2014). Typically, within medical illness,
a cognitive-behavioral (CB) model of health anxiety is applied. The CB model of health
anxiety is based on Lazarus and Folkman’s (1984) theory, which states that, in the
absence of psychological arousal, how life events are appraised depends on whether the
situation is deemed “good” or “bad,” as well as the perceived causes of the event.
Therefore, a situation that is appraised as a threat will be placed in a negative category
and cause feelings of fear and anxiety (Lazarus & Folkman, 1984). Comparatively, the
CB model suggests that those at risk for health anxiety interpret medical information
negatively (i.e., as a threat) and that the appraisals are influenced by preexisting health
beliefs, beliefs about the disease (i.e., belief that breast cancer will lead to role changes
and, ultimately, death), and the amount of anxiety that occurs after the appraisal has been
made (Warwick & Salkovskis, 1990).
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Within the CB model of health anxiety, there are fundamental cognitions that lead
to the development or maintenance of the disorder that include perceived risk both for
illness diagnosis and severity, perceived ability to cope with the diagnosis, and perceived
effectiveness of available treatments (e.g., chemotherapy; Salkovskis & Warwick, 2001;
Warwick, 1989). The research on health anxiety, breast cancer, and genetic testing is
limited, with the majority of the research measuring generalized anxiety, state/trait
anxiety, or general distress. Nonetheless, Rimes et al. (2006) assessed patients’v (N =
218) responses to genetic counseling using the CB model of health anxiety. The results
were consistent with the CB model, as study participants’ preexisting health anxiety and
interpretations predicted levels of health anxiety and distress post-counseling (Rimes,
Salkovskis, Jones, & Lucassen, 2006). Interestingly, compared to those with a family
history of colon cancer, FDRs of breast and ovarian cancer patients were significantly
more anxious post-counseling (Rimes et al., 2006).
Perceived risk of having a positive genetic test is another important factor when
determining the rate of health anxiety that a person may experience. Research has shown
that prior to genetic testing, patients tend to overestimate their risk, but the majority of
the time, anxiety returns to baseline, especially if a patient feels that he or she has a
competent medical team (Burke et al., 2000; Cicero et al., 2017; Katapodi, Facione,
Humphreys, & Dodd, 2005; Sanders, Campbell, Sharp, & Donovan, 2003).
Nevertheless, Sanders et al. (2003) found that perceived risk and subsequent distress were
dependent on whether the individual had experienced the death of a relative from the
disease, because it brought about thoughts of his or her own mortality.
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In addition, factors have been found to account for higher levels of both health
and generalized anxiety, including older age (younger women are more agreeable to
being in a surveillance program and less likely to experience health anxiety when they do
not undergo genetic testing), having children, a high level of uncertainty, a current
diagnosis of cancer, being unmarried, receiving a lower level of education, having a
lower level of optimism, and endorsing feelings of not being in control (Audrain et al.,
1997; Lodder et al., 2003).
In sum, premorbid health anxiety, preexisting interpretations about health, and
experiences with cancer in the family can all impact the amount of health anxiety that
occurs both before and after genetic testing. Health anxiety can increase the risk for
maladaptive behaviors (i.e., avoidance); however, genetic counseling can decrease health
anxiety if the following occurs: (a) the genetic counselor is aware of the individual’s past
medical, family, psychological, and emotional history and (b) the genetic counselor
provides enough information and education that a patient believes that he or she
understands his or her level of genetic risk (Meiser & Halliday, 2002).
Social problem-solving. Social problem-solving (SPS) is defined as how people
solve problems in their natural environments (D’Zurilla & A. M. Nezu, 1982, 1999). In
other words, SPS is the CB process that facilitates one’s own coping mechanisms
(adaptive or maladaptive) when faced with problems in everyday life (D’Zurilla & A. M.
Nezu, 1982, 1999). SPS consists of two processes: (a) problem-solving orientation (i.e.,
the motivational component: a negative or positive schema that influences whether a
person believes that everyday problems can be solved), and (b) problem-solving styles
(i.e., the person’s set of problem-solving skills: the cognitive and behavioral process that
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an individual uses to determine which coping mechanisms he or she should apply to the
problematic situation; A. M. Nezu, C. M. Nezu, & Perri, 1989).
The way in which a problem is approached and solved is based primarily on how
problems were solved in the past and how those situations shaped how a person thinks
and feels about his or her ability to solve problems effectively (D’Zurilla & A. M. Nezu,
1990). Research demonstrates the effectiveness of problem-solving training (SPS applied
in a treatment protocol) in a wide variety of settings and diagnoses (e.g., breast cancer
patients and increasing adherence in diabetes management; Hill-Briggs et al., 2011;
Hopko et al., 2011). Thus, it is not surprising that recent research has shown adaptive
SPS skills to be a protective factor against the psychological distress that may occur as a
result of cancer (Hopko et al., 2011). To illustrate, when an individual applies adaptive
problem-solving processes, he or she does not see the problem as one that cannot be
solved and, thus, engages a series of skills (e.g., running through a list of possible of
solutions and their alternatives) that decrease the chance that he or she will be unhappy
with the outcome (Chang et al., 2004).
Problem orientation. Problem orientation is a schema (negative or positive) that
influences how an individual copes with the everyday problems that he or she encounters
(D’Zurilla & A. M. Nezu, 1990). A. M. Nezu et al. (1989) explains that the cognitiveaffective-behavioral response guides the problem orientation and the problem-solving
process. The cognitive subcomponent of problem orientation is a set of fixed
attributions, appraisals, and expectations about problems and problem-solving that tend to
generalize across situations (D’Zurilla & A. M. Nezu, 1990). The emotional (affective)
state is the positive (e.g., hope) or negative (e.g., anger) feelings that are experienced in
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reaction to the problem (D’Zurilla & A. M. Nezu, 1990). How the individual chooses to
respond to the problem (i.e., weigh pros and cons versus avoidance) is the behavioral
subcomponent (D’Zurilla & A. M. Nezu, 1990). These subcomponents of problem
orientation dictate whether the person has a positive problem orientation (PPO) or a
negative problem-solving orientation (NPO; Chang et al., 2004).
PPO is a set of cognitive, affective, and behavioral skills that lend themselves to
adaptive problem-solving abilities (Chang et al., 2004). Those with a PPO tend to have
the following characteristics: (a) the ability to appraise problems as a positive challenge;
(b) the belief that problems can be solved, but that solving them may take time, effort and
perseverance; and (c) the belief that they have the ability to solve problems and the
willingness to invest in the problem-solving process (Chang et al., 2004). Conversely,
those with a negative problem orientation (NPO) tend to (a) see problems as a significant
threat, (b) doubt their own ability to solve problems effectively, and (c) are easily
discouraged when confronted with everyday problems (Chang et al., 2004).
A. M. Nezu et al. (1999) looked at the role of SPS in women (N = 105) with
newly diagnosed cancer (41% with breast cancer). The results demonstrated the
important role that adaptive (PPO) and maladaptive (NPO) problem-solving skills have in
the management of cancer-related distress. More specifically, patients with a NPO,
reported higher rates of depression, anxiety, and cancer-related distress (A. M. Nezu, C.
M. Nezu, Houts, Friedman, & Faddis, 1999). Similarly, McClure et al. (2012) assessed
problem-solving abilities, depression, and relationship satisfaction in 63 couples with one
partner diagnosed with cancer. The authors found that partners who viewed solving
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problems more positively were less likely to experience depression (McClure et al.,
2012).
Problem-solving styles. Problem-solving styles are the cognitive and behavioral
processes that determine which coping mechanisms are applied to problematic situations
(D’Zurilla & A. M. Nezu, 1990). Problem-solving styles include rational problem
solving (RPS), impulsivity/carelessness style (ICS), and avoidance styles (AS; D’Zurilla
& A. M. Nezu, 1990). RPS is an adaptive problem-solving style that is defined as the
deliberate and systematic application of effective problem-solving skills (D’Zurilla & A.
M. Nezu, 1990). Successfully applying RPS requires systematically collecting
information about the problem, identifying obstacles, setting realistic goals, generating a
list of alternative solutions, hypothesizing possible consequences of each solution,
weighing the pros and cons of each of the alternatives and implementing the chosen
solution, while also evaluating the outcome (D’Zurilla & A. M. Nezu, 1990).
In contrast to the positive and proactive RPS style, ICS and AS problem-solving
styles are considered dysfunctional. To illustrate, compared to the systematic problemsolving skills used in RPS, ICS is marked by impulsive choices, in which there is little
thought put into how to go about solving the problem and the consequences that could
result from the chosen solution. In other words, the first solution that comes to mind is
typically the solution that is implemented (D’Zurilla & A. M. Nezu, 1990). Similarly,
AS problem-solving includes avoidant behaviors, such as procrastination (D'Zurilla & A.
M. Nezu, 1990). These individuals avoid in the hopes that the problem will resolve on its
own and, and when problems do not resolve, accountability is often placed on others
(D’Zurilla & A. M. Nezu, 1990). In sum, the consistent use of ICS and AS problem-
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solving sets results in an inability to cope when confronted with problems which, over
time, lowers self-efficacy (D’Zurilla & A. M. Nezu, 1990; King et al., 2010). The
relationship between consistently poor problem solving, lower self-efficacy and
depression has been reported in both the diabetes self-management and suicidal risk
literature (D’Zurilla, Chang, Nottingham, & Faccini, 1998; King et al., 2010). In general,
the ability to apply adaptive problem-skills is related to higher self-efficacy and
optimism, which makes for improved coping and better adherence to treatment
recommendations (D’Zurilla et al., 1998; King et al., 2010).
Problem-solving training. The research on SPS and genetic testing decisions is
limited. Yet, there is literature to suggest that problem-solving training (PST) can
decrease distress (Schwartz et al., 1998). PST is a CB intervention that teaches people
how to choose and carry out the most effective coping strategies (D’Zurilla, 1988). PST
teaches patients how to proceed systematically through the problem-solving process and
includes the following components: (a) defining the problem (i.e., obtain information
about the problem, challenging cognitive distortions, set goals), (b) generate alternative
solutions, (c) decision making, and (d) solution implementation and verification (A. M.
Nezu, C. M. Nezu, Friedman, Faddis, & Houts, 1998).
Nezu et al. (1998) argued that cancer is a secondary stressor that makes dealing
with primary stressors (i.e., daily life events) much more stressful. Additionally, poor
premorbid problem-solving abilities increase the risk for cancer-related distress. Thus, it
is believed that improving SPS with PST can decrease general distress and cancer-related
distress (A. M. Nezu et al., 1999). Schwartz et al. (1998) demonstrated the effectiveness
of PST in 144 women who had family histories of breast cancer. The authors found that
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women who received PST showed a significant decrease in cancer-related distress
(Schwartz et al., 1998).
Prophylactic Treatment
The decision about whether to obtain genetic testing is complex due to the
overlapping social, emotional, and biological consequences (Calzone & Biesecker, 2002).
To decrease breast cancer risk, prophylactic treatment (e.g., mastectomy) is often
recommended to high risk FDRs who have received positive genetic test results
(Hartmann et al., 1999). Nevertheless, the decision to undergo major life-changing
surgery is not an easy one, especially for young women (Lerman et al., 2000). There are
numerous possible post-surgical outcomes that one may endure.
Prophylactic treatments can include mastectomy (removal of either one or both of
the breasts), oophorectomy (removal of the ovaries), chemoprevention (e.g., tamoxifen),
or surveillance (e.g., frequent mammograms; Meijers-Heijboer et al., 2000). Mastectomy
is typically recommended in high risk cases, with bilateral mastectomy decreasing the
risk of breast cancer by 95% (Rebbeck et al., 2004). Although older research established
a relationship between oophorectomy and decreased breast cancer risk in BRCA1
mutation carriers, more recent research has negated this finding (Heemskerk-Gerritsen et
al., 2015; Kotsopoulos et al., 2016; Rebbeck, Kauff, & Domchek, 2009). In addition to
or combined with surgical interventions, there are chemopreventive treatments such as
tamoxifen, which is an estrogen blocker that aids in the prevention of breast cancer
(Cuzick et al., 2015). Although tamoxifen decreases breast cancer risk, it increases
menopause-like symptoms and the risk for uterine cancer, which makes the treatment
undesirable to many women (Cuzick et al., 2015).
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It is should not be surprising that weighing the pros and cons of preventative
options can have a psychological impact. When considering prophylactic treatments,
level of cancer-related distress (i.e., anxiety; depression) can be exacerbated by younger
age, past history of diagnosis, perceived risk, having young children, and a family history
of cancer (Claes et al., 2005; Graves et al., 2012). In addition, changes in fertility and
body image are also significant components, as many of the women who are making
these decisions are younger than age 35. Conversely, there has been research that
suggests that prophylactic surgery can decrease psychological morbidity due to the
decrease in breast cancer risk (Brandberg et al., 2008). In general, the influence that
prophylactic treatment has on the genetic testing decision cannot be underestimated.
Summary
Genetic testing decisions are complex and uncertain. The decision can be
influenced by problem-solving abilities, health anxiety, and psychological distress.
Previous exposure to a family member’s battle with breast cancer can further intensify
and confound the decision (Dreer et al., 2009). Other factors contributing to the decisionmaking process are lack of resources (e.g., insurance, medical care, and education) and
previous health behaviors (e.g., eating habits and adherence to medical recommendations;
Lipscomb et al., 2012). The implications of this study are twofold: First, the relationship
between SPS, health anxiety, and psychological distress has yet to be evaluated in the
context of BRCA1/BRCA2 genetic testing and prophylactic decisions. Moreover,
significant findings may suggest that the assessment of one’s SPS skills, health anxiety,
and psychological distress should be incorporated into the pre- and post-genetic
counseling sessions. The ability to predict problem-solving skills post-genetic testing
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may allow medical providers to address these issues from the beginning, thus helping the
patients to feel empowered and to make decisions that are right for them. Second, by
examining SPS in relation to genetic testing, the hope was to provide a more concrete
explanation for genetic testing and prophylactic treatment decisions, as the current body
of literature is fairly small and inconsistent. Thus, using hypothetical vignettes and a
healthy sample, the aim of the current study was to determine how SPS, health anxiety,
and psychological distress influence genetic testing and prophylactic decisions.
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Chapter 3: Hypothesis
This study explored the relationship between genetic testing decisions, SPS
variables (i.e., problem-solving orientation, rational problem-solving style, avoidance and
impulsivity/carelessness), psychological distress, and healthy anxiety. This was
examined by providing a healthy population with hypothetical vignettes about specific
breast cancer scenarios.
Hypothesis
It was hypothesized that when provided with hypothetical vignettes in which a
first degree relative has been found to have the BRCA1 and/or BRCA2 mutation, PPO,
NPO, RPS, AS, ICS, levels of psychological distress, and/or health anxiety would predict
the likelihood of whether women would elect to obtain genetic testing and/or
prophylactic treatment.
Rationale
Individuals who utilize RPS are able to effectively and systematically define the
problem, generate alternatives, evaluate alternatives, implement solutions, and then
evaluate solutions. These individuals were surmised to be more likely to feel less
psychological distress than individuals who have less effective RPS skills. Conversely,
individuals with poor problem-solving abilities have a difficult time solving problems
effectively and have a tendency to solve problems in an impulsive and careless style.
Moreover, they also have a tendency to put off solving problems. This type of
dysfunctional problem-solving may lead to psychosocial distress. Similarly, persons with
high levels of health anxiety tend to make negative interpretations about health
information, which can lead to increased anxiety. In sum, regardless of decision,
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Chapter 4: Method
Research Design and Design Justification
In order to ensure the representativeness and generalizability of the sample, the
study used a cross-sectional design. The purpose of the current study was to examine the
relationship between genetic testing and prophylactic decisions, SPS variables (i.e.,
problem-solving orientation, rational problem solving, avoidance and
impulsivity/carelessness), psychological distress, and health anxiety. The variables of
interest were assessed by incorporating measures into an Internet survey format. Webpage-based surveys offer consistency, as they appear identical to all participants, have the
ability to target a large demographic, and obtain data in a systematic fashion (Gray,
Mann, & Stewart, 2001).
Participants and Recruitment
Due to the hypothetical nature of this study, the sample was drawn from a sample
of healthy women (N = 130). An effort was made to recruit a minimum of 102
participants to reflect a .05 alpha and medium effect size (Cohen, 1992). Participants
were between the ages of 18 and 35. The method of recruitment and study design
required participants to have access to the Internet. Efforts were made to recruit persons
from diverse racial backgrounds.
Inclusion criteria. Participants considered for this study were healthy adult
women with no prior or current diagnosis of breast cancer, no family history of breast
cancer (in first or second-degree relatives), and/or had never tested positive for the
BRCA1 or BRCA2 genetic mutation. Eligible participants were between the ages of 18
and 35, as research indicates that age is the biggest predictor in the decision to agree to
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genetic testing, and that women over the age of 35 are generally more willing to obtain
genetic testing (Alterkruse et al., 2010). Participants were fluent in English and at a sixth
grade reading level or higher, as determined by self-identification and the ability to
comprehend the informed consent. Participants of all races and ethnicities who met these
stated criteria were included.
Exclusion criteria. Participants with a current or prior breast cancer diagnosis,
the BRCA1 or BRCA2 genetic mutation, an FDR with a past or present history of cancer,
and/or a second degree relative diagnosed with breast cancer were excluded from the
study.
Recruitment. Recruitment for the study was done via ResearchMatch, a national
health volunteer registry that was created by several academic institutions and supported
by the U.S. National Institutes of Health as part of the Clinical Translational Science
Award (CTSA) program. ResearchMatch has a large population of volunteers who have
consented to be contacted by researchers about health studies for which they may be
eligible.
Procedure
Survey Monkey, an online resource used to create and administer surveys, was
used to obtain the data. Each survey included the informed consent, SPSI-R:S (D’Zurilla,
Nezu, & Maydeu-Olivares, 2002), Short Health Anxiety Inventory (SHAI; Salkovskis,
Rimes, Warwick, & Clark, 2002), Brief Symptom Inventory-18 (BSI-18; Derogatis,
2001), and a demographics questionnaire. The measures took approximately 30 minutes
to complete. After the survey was completed, participants were directed to a separate
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survey, where they had the option to enter their e-mail addresses for a 1 in 10 chance to
win a Target gift card. The lottery drawing occurred after recruitment ended.
Security. Considerable steps were taken to ensure the protection of study
participants. Prior to the initiation of the study, the Institutional Review Board of the
Philadelphia College of Osteopathic Medicine reviewed and approved the study.
Recruitment for the study conducted through ResearchMatch and all study participants
were recruited without coercion and were prompted to review the informed consent
thoroughly before proceeding. Participants were not identified by their names and all
data were kept confidential with the use of a secure e-mail address.
Measures
Clinical vignettes. Hypothetical vignettes were presented to study participants as
two distinct clinical scenarios, one addressing genetic testing decisions and the other
addressing prophylactic decisions (Appendix). Only those who indicated that they were
willing to obtain genetic testing were evaluated on prophylactic decisions.
Participants’ responses were scored on a Likert scale (extremely unlikely; unlikely;
likely; extremely likely). A neutral choice was not an option because in genetic testing
and prophylactic decisions, a choice must be made; thus, choice was forced in these
scenarios as well.
Social Problem-Solving Inventory-R:S (SPSI-R:S). The SPSI-R:S is a widely
utilized self-report measure that assesses everyday problem-solving abilities in five
domains (D’Zurilla et al., 2002). The SPSI-R:S assesses both problem orientation and
problem-solving style. Domains on the measure include, NPO, PPO, RPS, ICS and AS
(D’Zurilla & A. M. Nezu, 1999; Yetter & Foutch, 2014). The measure consists of 25
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items with five scales and a total global score (Dreer et al., 2009). Items are assessed on
a 5-point Likert-type scale ranging from 0 (not at all true of me) to 4 (extremely true of
me; Dreer et al., 2009). The scales have a standardized mean of 100 and a standard
deviation of 15. Scores equal to or above 145 are considered to be extremely above norm
group average and scores equal to or below 55 are considered to be extremely below
norm group average (D’Zurilla et al., 2002). The items on this measure have been found
to have satisfactory predictive, convergent, structural, and discriminant validity
(D’Zurilla et al., 2002). The internal consistency ranges from .60 to .90 and the testretest reliability ranges from .68 to .91 (D’Zurilla et al., 2002).
Short Health Anxiety Inventory (SHAI). The SHAI is an 18-item self-report
questionnaire that measures normal health concern and more severe health anxiety
(Salkovskis et al., 2002). The SHAI includes four statements that ask about the level of
health concerns over the past 6 months (Salkovskis et al., 2002). Items are scored from 0
to 3 and are added to obtain a main score, a negative consequences score. and a total
score ranging from 0 to 54 (Alberts, Hadjistavropoulos, Jones, & Sharpe, 2013). In the
development of the SHAI, Salkovskis et al. (2002) reported norm scores among nonpsychiatric populations for illness anxiety (M = 9.4; SD = 5.1), negative consequences (M
= 2.2, SD = 2.1), and total score (M = 12.2, SD = 6.2). The authors also reported the
health anxiety norm scores for the main section (M = 30.1, SD = 5.5), negative
consequences (M = 7.8, SD = 2.8), and total score (M = 37.9, SD = 6.8; Salkovskis et al.,
2002). Alberts et al. (2013) found that the internal consistency ranged from good to
excellent (.74 to .96).
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Brief Symptom Inventory-18 (BSI-18). The BSI-18 (Derogatis, 2001) is
derived from the 53 item BSI (Derogatis & Spencer, 1993), and the SCL-90-R (Derogatis
& Unger, 2010). The BSI-18 consists of three 6-item scales that measure both physical
and emotional complaints on a 5-point Likert scale that measure psychological distress
(Derogatis, 2001). Raw scores are converted into T-scores, and a T-score greater or equal
to 63 on any scale indicates a positive score for that scale. Overall distress is determined
by a T-score greater or equal to 63 on the Global Severity Index (GSI) or on two or more
of the subscales. The scales include somatization (SOMA), anxiety (ANX), depression
(DEPR), and the GSI (Derogatis, 2001). The BSI-18 has been found to be valid and
reliable in patients with varying medical and mental illnesses (Carlson et al., 2004).
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Chapter 5: Results
Statistical Analysis
A stepwise multiple regression was conducted to test the hypothesis that the SPS
variables, health anxiety, and psychological distress would predict genetic testing and
prophylactic decisions. Relevant assumptions of the statistical analysis were tested. The
assumptions of singularity and collinearity statistics were tested and all independent
variables were found to be sufficiently separate from each other (VIF = 1.00). Personal
information and predictor variables were analyzed with descriptive statistics (i.e.,
frequencies, means, standard deviations, and comparison), and Pearson product-moment
correlations were conducted to identify possible relationships among variables.
Demographic Information
Descriptive statistics were calculated for all participants within the overall sample
(N = 130) to summarize basic features of the data. The mean age of the sample was
28.42 (SD = 3.15). Means and frequencies were used to describe the main characteristics
of the sample (Table 3). Any variable with missing data was replaced by using series
means.
One hundred and twenty-four participants reported their age, with 68.48% of
women being 27 or older (M = 28.42, SD = 3.15, age range: 18-35 years). Of the one
hundred and thirty participants who responded to the question of marital status, 60
reported being single, six engaged, 53 married, one divorced, zero widowed and 10 lives
with a domestic partner. 130 participants responded about their education, including two
with a high school diploma or GED, 9 with some college, six with an Associate’s Degree,
54 with a Bachelor’s or four-year degree, 45 with a Master’s or other graduate degree and
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14 with a doctorate or other professional degree. 130 answered about their employment
status, with 94 participants employed for wages, three that were self-employed, two that
were out of work but not currently looking for work, give that were homemakers and 26
students.

Table 3
Participant Demographics
%

N

Single

46.15

60

Married

40.77

53

Divorced

0.77

1

Engaged

4.62

6

Living with a domestic
partner

7.69

10

1.54

2

Some College

6.92

9

Associates Degree

4.62

6

Bachelor or 4-year degree

41.54

54

Masters or other graduate
Degree

34.62

45

Marital Status

Education
High School Graduate or
GED
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Doctoral or other
professional degree

34

10.77

14

72.31

94

Self-employed

2.31

3

Out of work but not
currently looking for
work
Homemaker

1.54

2

3.85

5

20.00

26

Employment Status
Employed for wages

Student

Health Behaviors
The demographics questionnaire asked questions about specific health behaviors
and diagnoses, including tobacco use, alcohol and drug use, past and current medical and
psychiatric diagnoses, and compliance with medical appointments and recommendations
(e.g., yearly physical, monthly self-breast exams, and gynecological appointments). Out
of the 130 participants who responded, 95.38% of participants denied tobacco use,
76.92% responded “yes” to current alcohol use, and 34.62% admitted to using
illicit/recreational drugs (current or past use was not indicated). When asked about
current medical diagnoses (N = 130), seasonal allergies (n = 6, 4.17%) and migraines (n
= 6, 4.17%) were the most prevalent. Anxiety (n = 41, 28.47%) and depression (n = 41,
28.47%) were the most frequently reported psychiatric disorders among participants (N =
130), followed by posttraumatic stress disorder (n = 7, 4.86%), bipolar disorder (n = 3,
2.08%), and attention-deficit/hyperactivity disorder (n = 6, 4.17%). The majority of
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participants indicated that they receive annual check-ups from their primary care
physicians (PCPs; n = 100, 69.44%) and OB-GYNs (ages 18-20: n = 25, 17.36%; ages
21-29, n = 65, 45.14%; ages 30-35, n = 58, 40.28%). In spite of these findings, more
than half of the participants reported that they do not perform breast self-exams on a
monthly basis (n = 100, 69.44%).
Hypothetical Vignettes
For Vignette 1 (Table 4), scores ranged from 1 to 5 (M = 4.33, SD = 0.96). More
than half (51%; n = 77) reported that they would be “extremely likely” to obtain genetic
testing, 36.11% (n = 52) said they “likely” would, 8.33% (n = 12) said it would be
“unlikely” for them to receive testing, and 2.08% (n = 3) said it would be “extremely
unlikely.” For Vignette 2 (Table 5), participants who answered “likely” or “extremely
likely” in Vignette 1 were asked to respond to a second vignette that addressed whether
they would be open to receiving prophylactic treatment (i.e., mastectomy) if they were
found to have the BRCA1 or BRCA2 genetic mutation. One hundred twenty-nine
participants responded (range = 1-4; M = 2.76, SD = 0.82). Fifty-eight participants
(38.40%) reported that they would be “likely,” 39 (25.80%) said “unlikely,” 24 (15.90%)
said “extremely likely,” and 8 (5.30%) said “extremely unlikely.”
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Table 4
Vignette 1: Descriptive Statistics Table
%
2.0
7.9
34.4
51.0

Extremely Unlikely
Unlikely
Likely
Extremely Likely

n
3
12
52
77

Table 5
Vignette 2: Descriptive Statistics Table
%
5.3
25.8
38.4
24.0

Extremely Unlikely
Unlikely
Likely
Extremely Likely

N
8
39
58
15.9

Social Problem-Solving
The mean score on the SPSI-R:S (Table 6) was 106.39 (SD = 13.21; range: 62135; 63 = very much below norm group average; 135 = above norm group average). The
majority of participants (N = 137) fell within the norm group average. Having average
problem-solving skills increases the likelihood that one will be able to cope effectively
and experience less psychological distress when negotiating stressful situations.
Table 6
Social Problem-Solving Inventory-Revised, Short Form Descriptive Statistics
Subscale

N

Minimum

Maximum

Mean

Standard
Deviation
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Positive
Problem
Orientation

137

62

131

98.94

16.61

Negative
Problem
Orientation

137

74

135

94.10

12.09

Rational
Problem
Solving

137

64

136

98.74

16.05

Impulsivity/
Carelessness
Style

137

73

134

92.36

11.34

Avoidance
Style

137

78

125

86.97

11.57

SPSIRS
Total Score

137

63

135

106.39

13.21

Health Anxiety
The SHAI (range: 0-54) has two distinct components. The first assesses the
person’s perceived likelihood that he or she will become ill (illness likelihood [IL]) and
the second assesses the perceived consequences of having the illness (negative
consequences of illness [NC]). The mean scores (N = 137; total SHAI: M = 29.37, SD =
5.63) of the components were IL (M = 29.37, SD = 5.14) and NC (M = 4.97, SD = 1.39).
Table 7 illustrates results of the SHAI.

Table 7
Short Health Anxiety Inventory Descriptive Statistics
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Subscale
Illness
Likelihood
(IL)
Negative
Consequence
of Illness
(NC)
Total Score

38

N

Minimum

Maximum

Mean

140

15

46

24.40

Standard
Deviation
5.14

140

3

10

4.97

1.39

140

19

53

29.37

5.63

Psychological Distress
The BSI-18 was used assess current psychological distress over the past 7 days.
In addition to the GSI (max raw score = 72), separate scores were calculated on three
subscales: SOM, DEP, and ANX, with six questions contributing to each subscale (max
raw score = 24). The mean scores on all subscales and the GSI showed increased levels
of psychological distress. Table 8 displays results of the BSI-18.

Table 8
Brief Symptom Inventory-18 (Scaled Scores) Descriptive Statistics
Subscale
Somatization
Depression
Anxiety
Global
Scaled Score

N

Minimum

Maximum

Mean

137
137
137
137

41
40
38
33

69
74
81
75

48.24
48.91
49.21
48.60

Standard
Deviation
7.33
8.50
9.01
8.57
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Stepwise Regression Analysis: Vignette 2
A multiple stepwise regression was completed to determine the best linear
combination of scores on the SPSI-R:S, SHAI, and BSI-18 for predicting
BRCA1/BRCA2 genetic testing decisions in hypothetical FDRs. It was hypothesized that
the three measures as well as problem-solving orientation and styles on the SPSI-R:S
(PPO, NPO, RPS, ICS, and AS) would predict the decision of whether to receive genetic
testing (Vignette 1) and, if yes, prophylactic treatment. PPO significantly predicted
prophylactic treatment decisions, F(1,121) = 3.97, p = .05. The adjusted R squared
equaled .024, meaning that 2.4% of the variance in prophylactic treatment decisions can
be predicted from PPO. Tables 9 through 13 depict the stepwise regression analysis.

Table 9
Stepwise Regression Model Summary
Model

Variable

R

R Square

1

PPO

.178

.032

Adjusted R
Square
.024

Std. Error of
the Estimate
.82064

Table 10
Stepwise Regression Model Summary, Change Statistics
Model

Variable

1

PPO

R Square
Change
.032

F Change

Df1

Df2

3.971

1

121

Sig. F
Change
.049
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Table 11
Stepwise Regression Model Summary, Excluded Variables
Model

Variable

Beta In

T

Sig.

Partial
Correlation

1

NPO

.016

.153

.879

.014

Collinearity
Statistics:
Tolerance
.723

RPS

.108

.954

.342

.087

.620

ICS

.020

.218

.828

.020

1.00

AS

-.030

-.307

.760

-.028

.854

BSI Global
Score

.084

.913

.363

.083

.957

HAI Total
Score

.094

1.02

.309

.093

.948

Sum of
Squares
2.674
81.488
84.163

Df

Mean
Square
2.674
.673

F

Sig.

3.971

.049

Table 12
ANOVA
Model
1

Regression
Residual
Total

1
121
122

Table 13
Collinearity Coefficients
Unstandardized
Coefficients
B

Unstandardized
Coefficient
Std. Error

Standardized
Coefficient
B

t

Sig.

1
Constant
PPO

1.88

.447

2.674

3.9

.049

Standard
Score

.009

.004

Model

.673
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Chapter 6: Discussion
Demographic Variables
In the current study, 51% of participants indicated that they would be “extremely
likely” to receive genetic testing. This is less than what has been reported in prior
research using hypothetical samples. As previously discussed, Ropka et al. (2006)
completed a systematic review of breast cancer genetic testing uptake rates in both
hypothetical and real scenarios. The authors determined that participants in hypothetical
situations were more amenable to testing than participants in real situations (mean
hypothetical genetic testing uptake rate = 66%; mean real genetic testing uptake rate =
59%). Indeed, the uptake rates reported in hypothetical and real breast cancer genetic
testing research are variable (range = 20% to 96%; Ropka et al., 2006). The reasons for
this variability are likely due to differences in study methodology, sampling strategy (i.e.,
reference versus convenience), recruitment setting, personal history of breast cancer,
and/or family history of breast cancer (Ropka et al., 2006). To illustrate, most studies
differ in how they operationally define and measure interest in genetic testing versus
intent to obtain genetic testing (Glanz, Grove, Lerman, Gotay, & Le Marchand, 1999).
Accordingly, the discrepancies in genetic testing uptake are partly attributable to a body
of research that has been unsystematic in its methodology (Bowen, Patenaude, & Vernon,
1999).
The current study faced some of the same issues as other research completed in
this area (e.g., homogenous sample; hypothetical, non-patient sample; convenience
sampling). As stated previously, the hypothetical nature and the homogeneity of the
sample have limited the representativeness and generalizability of the study findings to
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the national FDR BRCA1/BRCA2 demographic. The overall mean age for this sample
was 28.42 years, with the majority of participants being between the ages of 27 and 35.
The mean age of women who responded that they would be “extremely likely” or
“likely” to receive genetic testing was 28.50 years. The mean age of women who
reported that they would be “extremely likely” or “likely” to obtain prophylactic
treatment (i.e., mastectomy) was 29 years. The study only included women in the 18 to
35 age range because there is research suggesting genetic testing decisions in this age
range are uniquely complex because of this particular stage of development (i.e.,
achieving independence from their parents), the reproductive and physical repercussions
of having breast cancer (i.e., childbearing, changes in sexual functioning and body
image), and the national guidelines in the U.S. (Evans et al., 2016; Patenaude et al.,
2013).
Considering that the genetic testing research on young women FDRs is sparse, the
current study made the decision to incorporate women between the ages of 18 and 35 to
gain a better sense of the determinants of their possible distress, health anxiety, and
problem-solving processes. It is unclear whether the uptake rates reported in this study
are representative for several reasons: (a) this study was hypothetical and, because of this,
the sample cannot be generalized to women in real genetic testing situations and (b) even
though younger age is a predictor of willingness to obtain genetic testing, it may have
been helpful to include women over the age of 35. Seeing that this study was
hypothetical, that genetic testing uptake rates reported in the literature are variable, and
that little research has been done in young women in this area, it is unclear whether the
uptake rates reported in this study are representative.
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Women were also asked about their marital statuses, education levels,
employment statuses/types of employment, health information (i.e., medical/mental
health histories), health behaviors (i.e., engagement of monthly breast exams), and uptake
of yearly physicals and gynecological exams. The majority of women in this study had a
bachelor’s degree or higher and worked in healthcare professions. Nearly all of the
womenvi reported that they visit their PCPs for yearly physicals (69.44%); however,
women do not visit the OB-GYN as frequently for their yearly or biennial appointments
(ages 18-20: 17.36%; ages 21-29: 45.14%; ages 30-35: 40.28%). Correspondingly,
69.44% of women indicated that they do not give themselves monthly breast self-exams
(BSE). The American Cancer Society updated the breast cancer screening guidelines,
stating that monthly BSE is no longer necessary (Oeffinger et al., 2015). Nevertheless,
BSE is still strongly recommended in women who are at a higher risk of developing
breast cancer (NCCN, 2018). Therefore, although the study was hypothetical, the
decision was made to assess for BSE in the present study. In regard to psychiatric illness,
more than half the women (56.25%) in this sample reported the absence of any current or
prior psychiatric disorders. Depression and anxiety occurred in 28.47% of the women
but did not predict either the decision to obtain genetic testing or to seek prophylactic
treatment.
None of the demographic variables were found to be significantly predictive of
genetic testing and/or prophylactic decisions. The sample used in this study was
homogeneous and represented a group of women who worked primarily in healthcare and
who were more highly educated than women in the average population, which could
account for the lack of significant findings. Nonetheless, these findings are consistent
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with other research that has shown education level, marital status, and psychological
distress to be poorly predictive of genetic testing and prophylactic treatment decisions
(Bellcross et al., 2015; Meiser et al., 2000; Schwartz et al., 2002). A prior diagnosis of
cancer, family history of cancer (particularly in a mother or sibling), levels of cancerrelated distress, and degree of perceived risk are considered to be most predictive of
genetic testing uptake (Bellcross et al., 2015; Meiser et al., 2000; Metcalfe et al., 2008).
The fact that women in the current study reported low attendance to OB-GYN
appointments was somewhat unexpected. Yet, there is data to suggest that people who
have less education and are of lower SES visit their PCPs more frequently than those who
are of higher SES (Dunlop, Coyte, & McIsaac, 2000). Conversely, higher SES
individuals tend visit PCPs less but are more likely to be given referrals and attend
appointments with specialists (Dunlop et al., 2000). The present findings may have
implications for genetic testing and prophylactic treatment access in women from low
SES backgrounds. For instance, cost, logistical barriers, lack of support, and
psychological distress have all been identified as important factors for not following up
with genetic testing and are often issues that women from low SES backgrounds face
(Willis et al., 2017). Thus, to ensure that these obstacles do not hinder medical access to
specialists, it is important for medical providers to identify barriers to treatment early on.
Moreover, for the purposes of the current study, findings that higher SES populations are
less likely to visit their PCPs may explain the low uptake of medical visits that were
reported (i.e., the sample was more highly educated and may have come from higher SES
backgrounds).
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Psychological Distress, Health Anxiety, and Social Problem-Solving
The goal of this study was to determine whether SPS variables (i.e., problemsolving orientation, rational problem solving, avoidance, and impulsivity/carelessness),
psychological distress, and healthy anxiety predict genetic testing and prophylactic
treatment decisions in a hypothetical, non-patient sample. Assessment of these variables
was completed via a one-time survey in which participants were asked to complete three
questionnaires and respond to two hypothetical vignettes.
Results from this cross-sectional study revealed that mean scores fell within the
normal range on the BSI-18, SHAI, and SPSI-R:S (domains PPO, NPO, RPS, ICS, and
AS). In other words, women in this study did not demonstrate significant levels of
psychological distress or health anxiety and fell in the normal range for problem-solving
orientation and ability. With the exception of PPO, none of the questionnaires were
significantly predictive of willingness to obtain genetic testing or prophylactic treatments.
Specifically, scores on the BSI-18 ranged from low distress to clinically
significant distress, but clinical significance was not reached for any of the scales.
Likewise, SHAI scores were broad and ranged from extremely low to extremely high.
Subscale scores were higher than those in average non-psychiatric populations; however,
psychological distress was not found to be predictive of genetic testing or prophylactic
treatment decisions. These findings are consistent with prior research in which levels of
cancer-related distress and state-trait anxiety were measured after receiving genetic
testing. The psychological distress level of non-carriers returned to normal range pre- to
posttest and general levels of distress remained stable (Claes et al., 2005).
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Women’s scores on the SPSI-R:S fell within the average range. In all domains,
scores on this measure ranged from below the norm group average to above the norm
group average. Neither problem orientation nor problem-solving style was found to be
significantly predictive of genetic testing decisions. In regard to prophylactic decisions,
four out of the five domains (NPO, RPS, ICS, & AS) and the total score failed to predict
any variance in prophylactic treatment choice. In contrast, PPO was found to
significantly predict prophylactic treatment decisions (i.e., mastectomy).
It is worth mentioning that having children can influence genetic and prophylactic
treatment decisions, even in hypothetical populations (Meijers-Heijboer et al., 2000).
Regrettably, the present study did not ask participants if they had children and the
opportunity was missed to evaluate this variable; however, three women in the study
(between the ages of 30 and 35) indicated they were currently pregnant. In healthy
women, it is widely recognized that carrying more than one baby to full-term reduces
breast cancer risk (Lecarpentier et al., 2012). Conversely, there is research to suggest that
increased estrogen production in pregnancy increases breast cancer risk in BRCA1
mutation carriers (Andrieu et al., 2006; Antoniou et al., 2006; Lecarpentier et al., 2012;
Milne et al., 2010). The research on the risk of pregnancy and breast cancer in BRCA2
mutations is inconclusive (Friebel et al., 2014).
Of the three pregnant women, two responded that they would be willing to receive
both genetic testing and prophylactic treatment. The third participant was agreeable to
genetic testing but stated that she would not accept prophylactic treatment. The women
did not endorse significant symptoms of psychological distress or health anxiety.
Interestingly, the participants who were agreeable to both vignettes yielded RPS scores
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on the SPSI-R:S that were below norm average (i.e., these women may have below
average problem-solving abilities). Although these findings are not meant to indicate
significance, the data emphasize the complicated decisions that premenopausal women
are confronted with when making these types of decisions.
The implications of the current findings are important because PPO has been
found to facilitate psychological distress reduction. McInerney-Leo et al. (2004) assessed
psychological well-being in 212 individuals from HBOC families. Regardless of genetic
testing decision (85% were agreeable), participants were randomized to receive either
PST or client-centered counseling. Those who received PST experienced a significant
decrease in distress compared to those who received client-centered counseling
(McInerney-Leo et al., 2004). Thus, regardless of decision choice, a PPO during real-life
genetic testing may increase confidence in the ability to make decisions, despite the
outcome. These results should to be interpreted with caution, as the amount of variance
that predicted prophylactic treatment decisions was small (2.4%), and it is possible that
other variables in the study impacted how the question was answered (e.g., education
level, age).
It is not surprising that this study did not generate significant levels of
psychological distress or health anxiety but did show a relationship between PPO and
treatment decisions. In the literature, individuals with a PPO typically present with
decreased levels of distress and generalized problem-solving self-efficacy (i.e., the belief
that one is capable of solving problems and carrying out solutions effectively; Nezu,
2004). For example, research shows that being able to assert more control over chronic
pain leads to a decrease in functional impairment (Shaw, Feuerstein, Haufler, Berkowitz
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& Lopez, 2001; Suso-Ribera, Camacho-Guerrero, McCracken, Maydeu-Olivares, &
Gallardo-Pujol, 2016).
The pain literature regarding self-management and control demonstrates the value
of self-efficacy (Lackner, Carosella, & Feuerstein, 1996). For example, functional selfefficacy expectancy—the view that an individual has the ability to complete work tasks
effectively—is a better predictor of adaptive coping than psychological distress or
perceived pain control (Lackner et al., 1996). The mechanism underlying the relationship
between positive problem-solving and increased self-efficacy is thought to be the result
of operant learning (Shaw et al., 2001). Put another way, how a person responds to
problems in his or her daily life will generate behavioral responses, some of which will
be reinforced and some of which that will not be (e.g., less distress in response to genetic
testing or prophylactic decisions acts as negative reinforcement; Shaw et al., 2001).
Thus, regardless of the decision, the ability to successfully implement effective problemsolving skills in the context of genetic testing and prophylaxis may be a protective factor
against the onset of psychological morbidity.
Implication of the Research Findings
Findings of the present study show that in hypothetical samples, levels of
psychological distress, health anxiety, and problem-solving ability are not predictive of
BRCA1/BRCA2 genetic testing decisions. In contrast, PPO is predictive of prophylactic
treatment decisions (i.e., mastectomy), whereas the other study variables are not. This
study is novel in that it is the first to show a specific relationship between problemsolving orientation, BRCA1/BRCA2 mutation status, and prophylactic treatment
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decisions. This finding advances the idea that positive problem-solving abilities aide in
the decision-making process in high risk HBOC families (Caplan, 1981; Pasacreta, 1999).
Research in genetic testing decisions in individuals at risk for the Huntington’s
disease genetic mutation has demonstrated similar findings. Perceived risk, although
important, was found to be secondary to one’s personality profile and coping mechanisms
(Decruyenaere et al., 1996). Similarly, a follow-up study found that individuals who
chose to obtain genetic testing were more likely to employ active problem-solving skills,
report a higher frequency of optimistic thoughts, and seek support more often (EversKiebooms, Welkenhuysen, Claes, Decruyenaere & Denayer, 2000). Nevertheless, since
this study did not find problem-solving orientation or style to be significantly predictive
of genetic testing decisions and research on SPS in prophylactic decisions is limited, it
remains unclear at this time whether findings of that nature can be applied to the current
study. Moreover, though the findings from this study are intriguing, there continues to be
a lack of consensus as to what providers should be addressing with patients (e.g.,
premorbid psychiatric illness, cancer related psychological distress versus perceived
risk). Although hypothetical, the current findings add to a growing body of research
suggesting that assessment of psychological variables and coping mechanisms should be
integrated into the initial genetic counseling session (Koch & Svendsen, 2005.
To emphasize the importance of considering SPS within the domain of
prophylactic decisions, Koch and Svendsen (2005) hypothesized that cancer genetic
testing is inherently non-directive and that effective genetic counseling provides
direction, thus increasing one’s sense of autonomy and informed consent. Therefore, the
genetic counselor’s task is to ensure that the patient feels fully informed about all aspects
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of the genetic testing process (e.g., risk, the treatment consequences of receiving a
positive result). The nature of BRCA1/BRCA2 genetic testing is to present prophylaxis
as the solution the problem of the possibility of being positive for the mutation. Thus,
patients engage in a process in which their problems are viewed in the context of the
available solutions, which can increase optimism and self-efficacy and protect against
psychological distress and health anxiety (Casey & Edgerton, 2008; Spector & Kitsuse,
2001).
It makes sense that a solution-focused strategy combined with feelings of
autonomy may lead to increased optimism and self-efficacy, thus making the problemsolving and decision-making processes empowering versus distressing. Further, patients
who have a stronger sense of self-efficacy, internal sense of control, and optimism may
choose prophylactic approaches, which are consistent with an active rather than passive
approach to problem-solving. The findings of past research and the current study
highlight that providers involved in the dissemination of information on genetic risk
should be take the time to ensure that patients have understood the information that has
been provided to them adequately. With this in mind, successfully navigating genetic
and prophylactic treatment decisions means acquiring information that may lead to or
exacerbate psychological distress and health anxiety. Even though this study did not find
a predictive relationship between psychological variables and genetic testing or
prophylactic decisions, it revealed evidence that problem-solving ability is asserting some
influence on the decision-making process. Thus, problem-solving ability may need to be
considered when asking women at risk for breast cancer to make complex decisions
about their future health.

PROBLEM-SOLVING AND CANCER DECISIONS

51

Limitations of Current Study
Similar to other studies in HBOC domain, the sample used in the current study
was fairly homogeneous, particularly in regard to education and profession, and may not
generalize to the entire population. It is important to note that due to human error,
information on race and ethnicity was not collected; however, pending IRB approval,
study subjects will be contacted and asked to fill out race and ethnicity information in a
separate survey. In addition, groups were not balanced by age, which led to a large
proportion of study participants being older than 27.
Another limitation of this study was the use of hypothetical vignettes versus a real
sample of women undergoing genetic testing and/or prophylactic treatment decisions.
According to the diathesis-stress model, a life stressor such as cancer could trigger the
onset of psychiatric illness (Vitaliano et al., 1998; Zubin & Spring, 1977). Thus, since
the study participants were not actually in the situation of being genetically tested or
having to decide whether to get a mastectomy, no stress was triggered and, consequently,
they were less likely to experience psychological distress or health anxiety. These issues
may limit the external validity, thus impacting the generalizability of the study.
In terms of other variables, the younger age of this cohort may have impacted
level of breast cancer knowledge as well as the overwhelming willingness to receive both
genetic testing and prophylactic treatment. Over the course of their lifetimes, this group
of women had more access to health literacy via school and/or technology (e.g., the
Internet) than generations in the past. Access to these resources may have increased the
awareness of breast cancer risk, breast cancer screening, available breast cancer
treatments, and the consequence of not following screening guidelines. For example,
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through the use of a text messaging intervention, a recent study demonstrated a
significant increase in cervical cancer screenings (Lee, Koopmeiners, Rhee, Raveis, &
Ahluwalia, 2014). This research highlights how technology has changed the ways in
which young people in today’s societies gather information to make informed medical
decisions. Finally, this study failed to consider women of Ashkenazi Jewish descent,
who are at a higher risk for breast cancer.
Future Directions
The impact of genetic testing and prophylactic decisions on psychological
functioning should not be minimized. Despite the limitations of this study, it was one of
the first to demonstrate that SPS, specifically PPO, is predictive of BRCA1/BRCA2
prophylactic treatment decisions. Future research should look at these relationships in
larger non-hypothetical samples and in different disease groups to determine whether the
results differ. More specifically, BRCA1/BRCA2 mutations are also responsible for
other cancers, most notably ovarian cancer; therefore, the next step may be to assess the
study variables in the context of ovarian cancer.
In addition, considering that SPS has been found to be quite successful in
decreasing psychological distress, it stands to reason that incorporating problem-solving
measures and problem-solving therapy into pre- and post-genetic counseling sessions
may alleviate short and/or long-term distress (McInerney-Leo et al., 2004). Accordingly,
developing a more comprehensive understanding of the ways in which SPS, health
anxiety, and psychological distress impact genetic testing and prophylactic decisions may
provide valuable insight into how to better assist patients and their families and medical
providers. Nevertheless, as previously discussed, the majority of research in this area
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either has methodological issues or is sparse, which may be why there continues to be
disagreement in the literature. If possible, efforts should be made to standardize
treatment protocols (i.e., through the development of randomized control trials) and to
incorporate heterogeneous samples. Finally, further investigation of SPS, psychological
distress, and health anxiety in BRCA1/BRCA2 genetic mutations among different races,
ethnic groups, and genders is warranted.
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Appendix
Clinical Vignettes
1. You have a family history of Breast Cancer in one of your first-degree relatives (mom
or sister). You recently found out that your mother is a carrier of the breast cancer
gene. You discuss your concerns with your OB-GYN who suggests that you see a
genetic specialist for further testing. The testing will determine if you carry certain
genes that increase your chances of getting breast cancer. What is the likelihood that
you would receive the genetic testing?
2. In the previous question you indicated you would be “Likely” or “Extremely Likely”
to obtain genetic testing. Please read the information below and consider the
following scenario: Based on the situation described, if you were found to have the
BRCA1 or BRCA2 gene would you elect to have your breasts surgically removed to
decrease your chances of getting breast cancer? Breast removal reduces the chance of
getting breast cancer by 90-95%.
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Endnotes
1

SEER (Surveillance, Epidemiology, and End Results Program) 9 Registry: Contains epidemiological

information from 1973 and later for Connecticut, Detroit, Hawaii, Iowa, New Mexico, San FranciscoOakland, and Utah. Seattle-Puget Sound and Atlanta joined Seer in 1974.

2

SEER 13 Registry: Contains all information included in Seer 9 Registry as well as Los Angeles, San

Jose-Monterey, Rural Georgia and the Alaska Native Tumor Registry. Data from 1992 and later is included
for these registries. These registries report on expanded race.

3

Number of New Cases and Deaths Per 100,000 People (All Races, Males and Females), Age-Adjusted

4

Patients had a family history of breast, ovarian or colon cancer.

5

Note: Groups were unbalanced, Age: 18-20: 3 subjects; 21-29: 80 subjects; 30-35: 5 subjects

